Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients
활용도 Analysis
논문 Analysis
연구자 Analysis
'
Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients' 의 참고문헌
Tumor-associated B7-H1 promotes T-cell apoptosis : a potential mechanism of immune evasion
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA) : a phase 3, open-label, randomised controlled trial
The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer : a systematic review
The importance of exosomal PDL1 in tumour immune evasion
Soluble programmed death-ligand 1(sPDL1)and neutrophilto-lymphocyte ratio(NLR)predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy
Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade
Soluble B7-H1 : differences in production between dendritic cells and T cells
Signatures of mutational processes in human cancer
Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer
Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial
Prognostic value of the neutrophil to lymphocyte ratio in lung cancer : a meta-analysis
Prognostic value of C-reactive protein and neutrophilto-lymphocyte ratio in patients with hepatocellular carcinoma
Prognostic implications of soluble programmed deathligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer
Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer
Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma
PD-1 and its ligands in tolerance and immunity
Oesophageal and gastric cardia adenocarcinomas : analysis of regional variation using the Cancer Incidence in Five Continents database
Nivolumab in patients with advanced gastric or gastrooesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12, ATTRACTION-2) : a randomised, double-blind, placebo-controlled, phase 3 trial
Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications
Inflammation in gastric cancer : interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
High levels of the soluble programmed death-ligand(sPDL1)identify hepatocellular carcinoma patients with a poor prognosis
FDA grants accelerated approval to pembrolizumab for advanced gastric cancer
Evaluating discrimination of risk prediction models : the C statistic
Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology
Docetaxel 75 mg/m(2)is active and well tolerated in patients with metastatic or recurrent gastric cancer : a phase II trial
Circulating PDL1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012
'
Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients'
의 유사주제(
